Levodopa prodrugs, and compositions and uses thereof

Details Levodopa prodrugs, and compositions and uses thereof Levodopa prodrugs, and compositions and uses thereof

2005-06-03

2008-03-11

Puttlitz, Karl (Department: 1621)

Organic compounds -- part of the class 532-570 series

Organic compounds

Amino nitrogen containing

C564S192000, C560S129000

Reexamination Certificate

active

07342131

ABSTRACT:
Prodrugs of levodopa, methods of making prodrugs of levodopa, methods of using prodrugs of levodopa, and compositions of prodrugs of levodopa are disclosed.

REFERENCES:
patent: 3811444 (1974-05-01), Heller et al.
patent: 3962414 (1976-06-01), Michaels
patent: 3992518 (1976-11-01), Chien et al.
patent: 4066747 (1978-01-01), Capozza
patent: 4070347 (1978-01-01), Schmitt
patent: 4079038 (1978-03-01), Choi et al.
patent: 4083949 (1978-04-01), Benedikt
patent: 4093709 (1978-06-01), Choi et al.
patent: 4134991 (1979-01-01), Wermuth
patent: 4311706 (1982-01-01), Bodor et al.
patent: 4663349 (1987-05-01), Repta
patent: 4771073 (1988-09-01), Repta
patent: 4826875 (1989-05-01), Chiesi
patent: 4873263 (1989-10-01), Repta
patent: 4966915 (1990-10-01), Tsuchiya et al.
patent: 5017607 (1991-05-01), Chiesi
patent: 5462933 (1995-10-01), Kramer et al.
patent: 5607969 (1997-03-01), Milman et al.
patent: 5827819 (1998-10-01), Yatvin et al.
patent: 5840756 (1998-11-01), Cohen et al.
patent: 2002/0099041 (2002-07-01), Gallop et al.
patent: 2003/0158254 (2003-08-01), Zerangue et al.
patent: 309 827 (1992-01-01), None
patent: 58024547 (1983-02-01), None
patent: 198604579 (1986-08-01), None
patent: WO 86/04579 (1986-08-01), None
patent: WO 88/01615 (1988-03-01), None
patent: WO 02/28882 (2002-04-01), None
Garzon-Aburbeh et al., Journal of Medicinal Chemistry (1986), 29(5), 687-91.
Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed. 1990. pp. 463-473.
U.S. Appl. No. 11/145,280, filed Jun. 3, 2005, Xiang et al.
Fix et al., “A Comparison of Oral and Rectal Absorption of L-Dopa Esters in Rats and Mice,”Pharm. Res., 7(4):384-387 (1990).
Gennaro (Ed.), Title Page and Table of Contents, in :Remington's Pharmaceutical Sciences, 17th Edition, Mack Publishing Co., Easton, PA, 5 pages (1985).
Marrel et al., “L-DOPA esters as potential prodrugs,”Eur. J. Med. Chem. Chim. Ther., 5:459-465 (1985).
International Search Report and Written Opinion mailed Nov. 3, 2005, for Application No. PCT/US2005/019492, filed Jun. 3, 2005.
International Search Report and Written Opinion mailed Nov. 3, 2005, for Application No. PCT/US2005/019493, filed Jun. 3, 2005.
Bai. 1995, “pGlu-L-Dopa-Pro: A Tripeptide Prodrug Targeting the Intestinal Peptide Transporter for Absorption and Tissue Enzymes for Conversion,”Pharmaceutical Research, 12(7): 1101-1104.
Bodor et al., 1977, “Improved Delivery through Biological Membranes. 4. Prodrugs of L-Dopa,”Journal of Medicinal Chemistry, 20(11): 1435-1445.
Coleman et al., 1990, “Polymer reviews: A practical guide to polymer miscibility,”Polymer, 31: 1187-1203.
Cooper et al., 1987, “L-Dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease,”J. Pharm. Pharmacol., 39: 627-635.
Di Stefano et al., 2001, “Dimeric L-Dopa Derivatives as Potential Prodrugs,”Bioorganic&Medicinal Chemistry Letters, 11: 1085-1088.
During et al., 1989, “Controlled Release of Dopamine from a Polymeric Brain Implant: In Vivo Characterization,”Ann. Neurol., 25(4): 351-356.
Felmeister, 1970, Chapter 86: Powders: Particle size reduction, classification, and measurement-mixing of powders—powders as a dosage form, pp. 1626-1628 fromRemington's Pharmaceutical Sciences, Fourteenth Edition, Hoover (ed.), Mack Publishing Company, Easton, PA.
Fincher, 1968, “Particle Size of Drugs and Its Relationship to Absorption and Activity,”J. Pharm. Sci., 57(11): 1825-1835.
Fix et al, 1989, “Short-Chain Alkyl Esters of L-Dopa as Prodrugs for Rectal Absorption,”Pharmaceutical Research, 6(6): 501-505.
Garzon-Aburbeh et al., 1986, “A Lymphotropic Prodrug of L-Dopa: Synthesis, Pharmacological Properties, and Pharmacokinetic Behavior of 1,3-Dihexadecanoyl-2-[(S)-2-amino-3-(3,4-dihydroxyphenyl)propanoyl]propane-1,2,3-triol,”J. Med. Chem. 29: 687-691.
Goodson, 1984, Chapter 6: Dental Applications, pp. 115-138 fromMedical Applications of Controlled Release, vol. II:Applications and Evaluation, Langer and Wise (eds.), CRC Press, Inc., Boca Raton, FL.
Greene and Wuts (eds.), 1991, Title page, Preface, and Contents fromProtective Groups in Organic Synthesis, Second Edition, John Wiley & Sons, Inc., New York.
Greene and Wuts (eds.), 1999, Title page, Prefaces, and Contents fromProtective Groups in Organic Synthesis, Third Edition, John Wiley & Sons, Inc., New York.
Harrison et al. (eds.), 1971-1995, Title pages, Prefaces, and Contents fromCompendium of Synthetic Organic Methods, vols. 1-8, John Wiley & Sons, Inc. New York.
Hisaka et al., 1990, “Absorption of a Novel Prodrug of L-Dopa, L-3-(Hydroxy-4-Pivaloyloxphenyl)alanine (NB-355): In Vitro and In Situ Studies,”Drug Metabolism and Disposition, 18(5): 621-625.
Hoes and Feijen, 1989, The Application of Drug-Polymer Conjugates in Chemotherapy, pp. 57-109 fromHorizons in Biochemistry and Biophysicsvol. 9:Drug Carrier Systems, John Wiley & Sons, New York.
Howard et al., 1989, “Intracerebral drug delivery in rats with lesion-induced memory deficits,”J. Neurosurg., 71: 105-112.
Ishikura et al., 1995, “Drug delivery to the brain. DOPA prodrugs based on a ring-closure reaction to quaternary thiazolium compounds,”Int'l. Journal of Pharmaceutics, 116: 51-63.
Juncos et al., 1987, “Levodopa methyl ester treatment of Parkinson's disease,”Neurology, 37: 1242-1245.
King and Schwartz, 1985, Chapter 90: Oral Solid Dosage Forms, pp. 1603-1632 fromPharmaceutical Sciences, Mack Publishing Company, Easton, PA.
Langer, 1990, “New Methods of Drug Delivery,”Science, 249: 1527-1533.
Langer and Peppas, 1983, “Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review,”JMS-Rev. Macromol. Chem. Phys., C23(1): 61-126.
Langer and Wise (eds.), 1984, Title page and Table of Contents fromMedical Applications of Controlled Release, vol. I:Classes of Systems andvol. II:Applications and Evaluation, CRC Press, Inc., Boca Raton, FL.
Larock, 1999, Title Page and Contents fromComprehensive Organic Transformations: A Guide to Functional Groups, Second Edition, Wiley-VCH, New York.
Leong and Langer, 1987, “Polymeric controlled drug delivery,”Advanced Drug Delivery Reviews, 1: 199-233.
Leppert et al., 1988, “The Effects of Carbidopa Dose and Time and Route of Administration on Systemic L-Dopa Levels in Rats,”Pharmaceutical Research, 5(9): 587-591.
Levy et al., 1985, “Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate,”Science, 228: 190-192.
Linhardt, 1989, Chapter 2: Biodegradable Polymers for Controlled Release of Drugs, pp. 53-95 fromControlled Release of Drugs: Polymers and Aggregate Systems, M. Rosoff (ed.), VCH Publishers.
Lu and Yu, 1994, “Dimensionless presentation for drug release from a coated pure drug bead: 2. Experiment,”International Journal of Pharmaceutics, 112: 117-124.
March, 1992, Title page and Contents fromAdvanced Organic Chemistry: Reactions, Mechanisms, and Structure, Fourth Edition, John Wiley & Sons, New York.
Roff et al. (eds.), 1971, Title Page, Preface, Acknowledgements, Contents, How to Use This Book, 1. List of Sections on Individual Polymers, and 2. List of Sections on Specific Properties and Related Information fromHandbook of Common Polymers: Fibres, Films, Plastics and Rubbers, CRC Press, Cleveland, OH.
Sasahara et al., 1980, “Dosage Form Design for Improvement of Bioavailability of Levodopa II: Bioavailability of Marketed Levodopa Preparations in Dogs and Parkinsonian Patients,”Journal of Pharmaceutical Sciences, 69(3): 261-265.
Saudek et al., 1989, “A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery,”N. Engl. J. Med., 321: 574-579.
Sefton, 1987, “Implantable Pumps,”CRC Critical Reviews in Biomedical Engineering, 14(3): 201-240.
Smith, 1994, Title Pag

Affiliated with

Also associated with

Rating

Levodopa prodrugs, and compositions and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Levodopa prodrugs, and compositions and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Levodopa prodrugs, and compositions and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3978444